Stockholders protest Pfizer's drug prices

Lenzer, Jeanne
July 2004
CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p24
Academic Journal
Reports on the criticism of the Interfaith Center on Corporate Responsibility (ICCR) against the pricing practices of a number of drug companies. Proposal on drug access submitted by ICCR at Pfizer's annual meeting in 2004; Statement from Adrian Dominican Sisters' coordinator Margaret Weber about the proposal; Position of Pfizer chairman Henry A. McKinnell Jr. regarding the ICCR proposal; Contributions of Pfizer to political action committee and campaign funds.


Related Articles

  • COMPANY SPOTLIGHT: Pfizer.  // PharmaWatch: CNS;February 2003, Vol. 2 Issue 2, p18 

    Presents a corporate profile of pharmaceutical company Pfizer. Company overview; Business description; Key employees including president and chairman Henry A. McKinnell and vice-president John F. Niblack; Strengths and weaknesses; Financial status; Products and services.

  • Pfizer to explain high cost of prescription drugs. Rosa, Taina // Caribbean Business;9/16/2004, Vol. 32 Issue 39, p18 

    Reports on the seminar aimed at explaining the reason for the high cost of medicine offered by pharmaceutical manufacturer, Pfizer Corp. in Puerto Rico. Outlook of the industry towards the high prices of medicine; Cost associated with developing a single product; Investments involved in research...

  • Pfizer takes leading role in drug-price debate. Arnold, Matthew // Medical Marketing & Media;Aug2004, Vol. 39 Issue 8, p32 

    Reports on the launch of Helpful Answer, the brand for beefed-up roster of patient assistance programs by Pfizer Inc. in the U.S. Effort of the pharmaceutical industry to alleviate the high cost of drugs to uninsured Americas; Leadership role of Pfizer Inc. in drug-price debate; Expansion of the...

  • TOP STORIES.  // MondayMorning;3/10/2008, Vol. 16 Issue 10, p1 

    Monday, March 10, 2008 / Vol. 16 / No. 10 MondayMorning Weekly Online News Update for the Healthcare Industry Monday, March 10, 2008 / Vol. 16 / No. 10 ©2008 MedContent, Inc / All Rights Reserved TOP STORIES Brand-Name Drugs Continue Sharp Price Increases. Drugmakers increased their...

  • Nexium 24HR's impact: How top brands respond.  // Drug Store News;8/25/2014, Vol. 36 Issue 8, p26 

    The article focuses on how drug retailers and consumers have been affected by the introduction of the Nexium 24HR over-the-counter (OTC) acid blocker by pharmaceutical company Pfizer Inc. Topics discussed include the decline of the dollar sales of the competitors of Nexium, the increase of the...

  • Market watch: Pricing strategies for emerging markets. Lineberry, Neil; Snyder, Eric; Gunda, Seema // Nature Reviews Drug Discovery;Aug2011, Vol. 10 Issue 8, p567 

    The article focuses on pricing strategies for pharmaceutical products in emerging markets. It states that identifying prices is a key challenge if one has to consider the annual income of the patient over the cost of his therapy. It mentions examples of pricing strategies employed on various...

  • Views from Pharma Leaders. Van Arnum, Patricia // Pharmaceutical Technology;Dec2011, Vol. 35 Issue 12, p29 

    The article offers insights from pharmaceutical industry leaders on the review of 2011 and an outlook for 2012. Michael Kleinrock of IMS Institute for Healthcare Informatics, notes the policy-driven actions which imposed additional costs to manufacturers or price cuts on medicines. John Kelly of...

  • Big Pharma Bets on Emerging Economies. Jack, Andrew // Global Health (Global Health Council);Winter2009, Issue 1, p22 

    The article looks at the trend of the pharmaceutical industry to expand their products to emerging markets such as India, China, and Brazil. According to the author, companies such as Merck & Co. Inc., GlaxoSmithKline, and Pfizer Inc., have been competing in regions such Asia and Latin America...

  • Public address. Kelly, Patrick // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p12 

    Reports that Pfizer president Patrick Kelly responded when "The Wall Street Journal" accused pharmaceutical companies of price increases that would wipe out gains in pharmaceutical benefits for low-income seniors covered by Medicare. Kelly's contention that the article gave a distorted view of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics